Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonism has been demonstrated to improve glucose intolerance and exendin-4, a GLP-1 receptor agonist, is currently being used for the treatment of type 2 diabetes mellitus. Recent studies suggest that GLP-1 may also ameliorate plasma triglyceride (TG) metabolism. In our previous study, we found exendin- 4 inhibited VLDL production by using APOE*3-Leiden (E3L) mouse, however, the mechanism underlying is still unclear. Therefore, the aim of this study was to evaluate the potential mechanism behind the inhibition of VLDL biosynthesis and secretion of exendin-4 in high fat diet-fed E3L mice.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
